Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Chan

Orthopaedic Surgery Lutz, FL Medical Doctor

NPI 1861473605 CMS profile 900163

4211 Vandyke Road, Suite 200, Lutz, FL 33558

Open in the dashboard

General payments

$14,474

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Chan of Lutz, FL is reported in the CMS Open Payments database as having received $14,474 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,969 35
2024 General $4,443 29
2023 General $662 19
2022 General $776 15
2021 General $2,117 34
2020 General $166 5
2019 General $2,339 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Chan
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to John Chan were reported at $3,969. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year John Chan Orthopaedic Surgery median Middle half National median
2019 $2,339 $644 $140–$2,844 $163
2020 $166 $312 $75–$1,860 $114
2021 $2,117 $520 $117–$2,495 $132
2022 $776 $598 $128–$2,731 $149
2023 $662 $461 $128–$2,264 $160
2024 $4,443 $497 $134–$2,475 $164
2025 $3,969 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $8,076 48 payments
  2. Smith+Nephew, Inc. $1,716 39 payments
  3. Coastal Medical Technologies LLC $1,158 14 payments
  4. Arthrex, Inc. $1,033 11 payments
  5. Stryker Corporation $752 9 payments
  6. Medtronic, Inc. $310 4 payments
  7. Ethicon US, LLC $304 5 payments
  8. Innovation Technologies Inc $252 3 payments
  9. DePuy Synthes Sales Inc. $129 5 payments
  10. Integra LifeSciences Corporation $117 4 payments
  11. Other $628 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,128 150 payments
  2. Travel and Lodging $6,279 22 payments
  3. Education $67 1 payment
Products named General payments · program years 2019–2025
  1. ROSA-Knee $1,392 7 payments
  2. Persona $1,327 3 payments
  3. ROSA $1,143 10 payments
  4. PICO 14 $642 11 payments
  5. RENASYS Touch $577 7 payments
  6. PICO $420 10 payments
  7. mymobility Platform $407 3 payments
  8. INSPACE $384 2 payments
  9. Renasys $348 4 payments
  10. Oxford $279 6 payments
  11. Other $4,833 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

406

Median for Orthopedic Surgery: 203

Drug cost

$4,620

Median for Orthopedic Surgery: $1,433

Branded share of claims

16.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 89 $2,055
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 67 $1,234
Meloxicam Generic 147 $773
Cephalexin Generic 58 $231
Mupirocin Generic 23 $169
Nabumetone Generic 22 $158

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$242,171

Of which drugs: $42,106

Medicare patients

463

Average age 74

Services billed

8,825

296 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 44%
Diabetes 29%
Chronic kidney disease 22%
Depression 21%
Osteoporosis 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 55 5,166 $25,808
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 22 36 $14,428
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 117 1,520 $130

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record